| | | |
PIN
|
P
|
Tumors
|
|---|
|
Genotype
|
Animals No
|
9cRA
|
Incidence
|
Frequency
| |
P
|
DO
|
|---|
|
p27+/+
|
18
|
0
|
11
|
0.16 ± 0.5
| |
0
|
0
|
|
p27+/+
|
17
|
+
|
0
|
0
|
0
|
0
|
0
|
|
p27+/-
|
16
|
0
|
60
|
1.5 ± 0.5*
| |
3
|
4
|
|
p27+/-
|
15
|
+
|
44
|
1.1 ± 0.6
|
0.05
|
2
|
4
|
|
p27-/-
|
15
|
0
|
70
|
2.0 ± 0.4*
| |
3
|
6
|
|
p27-/-
|
15
|
+
|
53
|
1.4 ± 0.5
|
0.005
|
4
|
6
|
- Animals were treated with MNU, 30 mg/kg body weight at the age of 2 months and followed until sacrifice between 7-12 months of age. PIN were identified in DLP by cutting longitudinally through the urethral part of the prostate. H&E staining was used for identification of PIN. Stepwise, 4 μm thick paraffin sections at three separate tissue levels 30 μm apart were cut and the number of PIN per prostate determined. Incidence, percentage of animals with PIN per group; frequency, number of PIN per animal. PIN were determined in various groups without knowledge of the treatment protocol. (P), prostate; (DO), distant organs; *, significant difference (p < 0.01) in the multiplicity of PIN between p27+/- and p27-/- mice;
